Metabolomics Reveals Metabolic Alterations by Intrauterine Growth Restriction in the Fetal Rabbit Brain

Erwin van Vliet1, Elisenda Eixarch1, Miriam Illa1, Ariadna Arbat-Plana1, Anna González-Tendero1, Helena T. Hogberg2, Liang Zhao2, Thomas Hartung2, Eduard Gratacos1*

1 Department of Maternal-Fetal Medicine, Institut Clinic de Ginecologia, Obstetricia i Neonatologia (ICGON), Hospital Clinic and Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain, 2 Johns Hopkins University, Bloomberg School of Public Health, Department of Environmental Health Science, Baltimore, Maryland, United States of America

Abstract

Background: Intrauterine Growth Restriction (IUGR) due to placental insufficiency occurs in 5–10% of pregnancies and is a major risk factor for abnormal neurodevelopment. The perinatal diagnosis of IUGR related abnormal neurodevelopment represents a major challenge in fetal medicine. The development of clinical biomarkers is considered a promising approach, but requires the identification of biochemical/molecular alterations by IUGR in the fetal brain. This targeted metabolomics study in a rabbit IUGR model aimed to obtain mechanistic insight into the effects of IUGR on the fetal brain and identify metabolite candidates for biomarker development.

Methodology/Principal Findings: At gestation day 25, IUGR was induced in two New Zealand rabbits by 40–50% uteroplacental vessel ligation in one horn and the contralateral horn was used as control. At day 30, fetuses were delivered by Cesarian section, weighed and brains collected for metabolomics analysis. Results showed that IUGR fetuses had a significantly lower birth and brain weight compared to controls. Metabolomics analysis using liquid chromatography-quadrupole time-of-flight mass spectrometry (LC-QTOF-MS) and database matching identified 78 metabolites. Comparison of metabolite intensities using a t-test demonstrated that 18 metabolites were significantly different between control and IUGR brain tissue, including neurotransmitters/peptides, amino acids, fatty acids, energy metabolism intermediates and oxidative stress metabolites. Principle component and hierarchical cluster analysis showed cluster formations that clearly separated control from IUGR brain tissue samples, revealing the potential to develop predictive biomarkers. Moreover birth weight and metabolite intensity correlations indicated that the extent of alterations was dependent on the severity of IUGR.

Conclusions: IUGR leads to metabolic alterations in the fetal rabbit brain, involving neuronal viability, energy metabolism, amino acid levels, fatty acid profiles and oxidative stress mechanisms. Overall findings identified asparagine, ornithine, N-acetylaspartylglutamic acid, N-acetylaspartate and palmitoleic acid as potential metabolite candidates to develop clinical biomarkers for the perinatal diagnosis of IUGR related abnormal neurodevelopment.

Introduction

Intrauterine Growth Restriction (IUGR) due to placental insufficiency occurs in 5–10% of gestations and is a major determinant of perinatal morbidity and mortality [1]. The compromised placental blood supply results in sustained hypoxemia and under-nutrition of the developing fetus [2], which can affect fetal programming of vital organs and an increased risk for disease later in life [3,4]. The fetal brain was shown to be particularly vulnerable to prolonged IUGR conditions [5–6]. Clinical imaging studies demonstrated structural changes in the brain of IUGR infants including altered white and grey matter volumes [7–8], decreased levels of brain connectivity [9] and delayed cortical development [10]. Moreover, several clinical studies in neonates and infants who suffered IUGR showed both short and long-term neurodevelopmental delays and cognitive dysfunctions [11–12].

The early perinatal diagnosis of IUGR related abnormal neurodevelopment represents a major challenge in fetal medicine. At present abnormal neurodevelopment is primarily diagnosed later in the child’s life and persists until late childhood and adolescence [13–14]. The ability to diagnose abnormal neurodevelopment during perinatal life would allow interventions during the critical window of opportunity of the first two years of life, when brain reorganization is particularly active and interventions have shown to be effective in reverting the effects of adverse fetal conditions [15]. The development of clinical biomarkers is considered a promising approach to predict and monitor abnormal neurodevelopment during perinatal life. Because the effects of IUGR on the fetal brain are subtle, the approach will...
likely involve the identification of sensitive biochemical and/or molecular imaging biomarkers [16]. The discovery and development of such biomarkers requires an improved understanding of the underlying molecular and biochemical mechanisms of IUGR related abnormal neurodevelopment.

Metabolomics is defined as the quantitative measurement of the dynamic metabolic response of living systems to genetic, physical, pathological or developmental factors [17]. The technology has emerged in numerous fields of research, including fetal medicine aiming to facilitate the understanding of fetal disease pathophysiology and discovery of predictive biomarkers [18]. Previous metabolomics studies have shown metabolic alterations in clinical samples including cord blood and urine samples of IUGR neonates [19–20]. Moreover, metabolomic profiling studies in animal IUGR models (e.g. rat and pig) pointed out alterations in blood plasma, serum and jejunum metabolome as potential biomarkers for the diagnosis of IUGR and its effects on fetal programming [21–23]. To the best of our knowledge, the effects of IUGR on the fetal brain metabolome have not yet been characterized.

The aim of this targeted metabolomics study was to obtain more mechanistic insight into the effects of IUGR on the fetal brain and identify potential metabolite candidates for the development of clinical biomarkers for IUGR related abnormal neurodevelopment. The study was undertaken in a rabbit model of IUGR, which mimics placental insufficiency by the selective 40–50% ligature of uteroplacental vessels [24]. Despite general species differences, brain development in the rabbit is similar to that of humans, but within a more compressed time-frame [25]. As in humans, the temporal pattern of oligodendrocyte maturation, myelination and functional changes occur most rapidly during the perinatal period, starting several days before birth and continuing during the postnatal period. Therefore the rabbit provides a relevant and useful model to study perinatal processes of brain development. Previous studies in the rabbit IUGR model, showed that IUGR leads to impairment, hemodynamic adaptation, alterations in white and grey brain matter and neurobehavioral changes, as observed in IUGR infants [24,26]. The findings of this targeted metabolomics study provide additional mechanistic insights into the effects of IUGR on the fetal brain and support the development of clinical biomarkers for the perinatal diagnosis or treatment of IUGR related abnormal neurodevelopment.

Materials and Methods

The Rabbit IUGR Model

All animal procedures in this study were approved by the Animal Experimental Ethics Committee of the University of Barcelona. Moreover animal handling and procedures were performed according the applicable regulations and guidelines of the Animal Experimental Ethics Committee of the University of Barcelona (Permit number: 2012/7684). The New Zealand pregnant rabbits were provided by a certified breeder and dams were housed for 1 week before surgery in separate cages on a reversed 12/12 hour light cycle, with free access to water and standard chow. IUGR was induced in two New Zealand pregnant rabbits at 25 days of gestation by uteroplacental vessels ligation as described in [24]. Briefly, after tocolysis and antibiotic prophylaxis administration, an abdominal midline laparotomy was performed under anaesthetic condition. Gestational sacs of both horns were identified and, in one uterine horn, 40–50% of the uteroplacental vessels of all gestational sacs were ligated, the contra lateral horn was used as control. After the procedure the abdomen was closed in two layers with a single suture of silk (3/0). Postoperative analgesia was administered and animals were again housed with free access to water and standard chow for 5 days until delivery and well-being was controlled each day. Cesarean section was performed at 30 days of gestation (term at 31 days) and nine living (five control and four IUGR) and seven stillborn (one control and six IUGR) fetuses were collected. After delivery, all living newborns were weighed and sacrificed by immediate decapitation. The fetal brains were removed, weighed and anterior hemisphere, posterior hemisphere, basal ganglia and brain stem regions were dissected on ice. The dissected brain tissues were snap frozen in liquid nitrogen and thereafter stored at −80°C for subsequent metabolomics analysis.

Sample Preparation Procedures

The frozen brain tissue regions were weighted and transferred to an Eppendorf tube. For metabolite extraction (25 μL/mg of tissue) ice cold high purity Methanol/Water mixture v/v 70/30 (Sigma Aldrich, Spain) was added. The brain tissues were disrupted (on ice) using an ultrasound sonicator (Qsonica, CT, USA) for 3–4 minutes until no more cellular debris was visible in the tissue homogenate. To control for potential differences in tissue quantities the total protein content of the homogenates was quantified using a protein assay (BioRad). A standard volume of 250 μL containing 10 mg of tissue was transferred to a new Eppendorf tube, stored for 1 hour at −20°C and centrifuged at 16,000 rcf, 4°C for 10 min. Supernatants were collected, transferred to a new eppendorf tube and evaporated to dryness at room temperature in a speedvac concentrator (Thermo Scientific). The dried samples were reconstituted in 60 μL of 60% MeOH with 0.1% FA and clarified by centrifugation at 14,000 rcf, 4°C for 5 minutes. The clarified samples were transferred to plastic HPLC vials for LC-QTOF-MS measurements.

Liquid Chromatography-quadrupole Time-of-flight Mass Spectrometry Measurements

The LC-QTOF-MS measurements were performed using an Agilent 1260 series LC binary pump and wellplate autosampler coupled to a 6520 accurate-mass Q-TOF LC-MS system equipped with a dual electrospray (ESI) ion source operated in negative-ion mode (Agilent Technologies, Santa Clara, CA). A Cogent Diamond Hydride ™ (MicroSol, Eatontown, NJ) aqueous normal phase (ANP) column (150x2.1 mm i.d., 4 μm particle size, 100 μm pore size) was used for separation of metabolites. The LC parameters were as follows: autosampler temperature, 4°C; injection volume, 5 μL; column temperature, 35°C; flow rate, 0.4 ml/min. The solvents and optimized gradient conditions for LC were: Solvent A, 50% methanol/ 50% water/0.05% formic acid; Solvent B, 90% acetonitrile with 5 mM ammonium acetate; elution gradient: 0 min–100% B; 20–25 min –40% B; post-run time for equilibration, 10 min in 100% B. A blank injection was run after every 3 samples. The optimized ESI Q-TOF parameters for MS experiments were: ion polarity, negative; gas temperature, 325°C; drying gas, 10 l/min; nebulizer pressure, 45 psig; capillary voltage, 4,000 V; fragmentor, 140 V; skimmer, 65 V; mass range, 70–1,100 m/z; acquisition rate, 1.5 spectra/s; instrument state, extended dynamic range (1,700 m/z, 2 GHz); Spectra were internally mass calibrated in real time by continuous infusion of a reference mass solution using an isotropic pump connected to a dual sprayer feeding into an electrospray ionization source. Data were acquired with MassHunter Acquisition software (Agilent Technologies, Santa Clara, CA).
Statistical Data Analysis

Data Processing and Metabolite Identification

Following LC-QTOF-MS data acquisition, the acquired raw data files were processed with Agilent MassHunter Qualitative Analysis software (version 5.0). Reproducibility of chromatograms was first inspected by overlaying the Total Ion Chromatograms (TICs) of all samples. Data files that showed extraneous peaks were excluded for further processing. To normalize the samples for differences in tissue quantities the OD values of the protein assay were integrated into the ion intensity quantification procedure. The normalization procedure was confirmed by a comparison of the total ion intensity of peaks in MS profiles. Initial, putative metabolite identification was achieved by searching the accurate m/z values of the peaks against an in-house built database derived from HMDB, KEGG, METLIN and other public databases. At the same time, the Extracted Ion Chromatograms (EICs) for these matched putative metabolites were generated by performing **Find by Formula** function integrated into the software. The abundance of the EICs was calculated by summing the intensities of all compound-related peaks (e.g. isotopic peaks, adduct peaks, etc.).

The pre-processed data files were imported into Agilent Mass Profiler Professional software (version 12.1) for further statistical analysis. MS/MS spectra and retention times acquired from reference metabolites were used for confirmation of the identification of statistically significant metabolites. More specifically, the exact m/z values and intensities of fragment ions from the acquired MS/MS spectra of putative metabolites must have a match of m/z values and extracted ion chromatograms against the metabolite database and subsequent manual check for matching scores and peak shapes resulted in the identification of metabolite intensities in the control and IUGR fetal brain tissue samples. The matching of m/z values and extracted ion chromatograms from the public databases (e.g. METLIN, MassBank), if available.

Statistical Data Analysis

To identify statistical significant differences between the control and IUGR fetal brain tissue samples the processed data files were imported into Agilent Mass Profiler Professional software version 12.1 (Agilent Technologies, Santa Clara, CA) for statistical analysis. The intensities of the 78 identified metabolites in control and IUGR brain tissue samples were compared using a t-test (cut-off p<0.05) followed by a Benjamini-Hochberg Multiple Testing Correction. To visualize the variation within the dataset and most contributing variables (metabolites), the significant metabolites were used to perform a Principal Component Analysis (PCA) using the first three components for data classification. A hierarchical cluster analysis was used to demonstrate if control and IUGR fetal brain tissue samples could be distinguished based on the profile of the significantly altered metabolites. Correlations between fetal birth weight and metabolite intensities were performed in Graphpad Prism version 5 (GraphPad software, San Diego, CA).

Results

Fetal Birth and Brain Weight of Control and IUGR Rabbit Fetuses

In total nine living (five control and four IUGR) and seven stillborn (one control and six IUGR) fetuses were collected. The mortality rate (60%) in the group of IUGR fetuses is inherent to the induced IUGR conditions and in accordance with previous studies [24]. The fetal birth and brain weight of the IUGR rabbit fetuses was significantly lower compared to the control fetuses (Table 1). The average birth weight for control fetuses (n = 5) was 52.73 ± 0.53 g and for IUGR (n = 4) 33.86 ± 7.17 g. The average brain weight was 1.32 ± 0.05 g for control and 1.07 ± 0.13 g for IUGR fetuses. One of the selected IUGR fetuses (I) had a relatively high birth weight of 44.54 g, which suggests it developed under less severe IUGR conditions compared to the other three IUGR fetuses.

Metabolic Differences between Control and IUGR Fetal Brain Tissue

The matching of m/z values and extracted ion chromatograms against the metabolite database and subsequent manual check for matching scores and peak shapes resulted in the identification of 78 metabolites. To investigate if IUGR leads to metabolic differences in the fetoplacental metabolism, the ion intensities of the 78 metabolites in the control and IUGR fetal brain tissue samples were compared using a t-test. Results showed that 18 of the 78 metabolites were significantly different (p<0.05). The statistically significant metabolites, their p-values and description are shown in Table 2. To visualize the metabolic differences, the mean metabolic intensities in the control and IUGR fetal brain tissue samples were plotted in graphs (Fig. 1A-D). The graphs showed that most metabolites were significantly decreased in the IUGR fetal brain tissue samples, including the brain metabolites; N-acetylaspartylglutamic acid (NAAG), N-acetylaspartate (NAA) and pyroglutamic acid, (Fig. 1A), the amino acids; ornithine, L-lysine, asparagine, histidine and leucine intermediate 2-keto-isovalerate, (Fig. 1B), the energy metabolism intermediates; succinate and panthothenate, oxidative stress metabolites malondialdehyde and 3-nitrotyrosine, the nitrogen containing heterocycle purine and organic acid 3,4-dihydroxybutyric acid (Fig. 1C). Metabolites that were significantly increased included the nucleotide GMP and

Table 1. The birth and brain weight of the collected control and IUGR rabbit fetuses.

| Control | IUGR |
|---------|------|
| **Fetus** | **Birth weight (g)** | **Brain weight (g)** | **Fetus** | **Birth weight (g)** | **Brain weight (g)** |
| A       | 52.57 | 1.33    | F       | 29.22 | 0.92    |
| B       | 52.63 | 1.36    | G       | 31.22 | 1.14    |
| C       | 52.53 | 1.35    | H       | 30.46 | 1.01    |
| D       | 53.63 | 1.25    | I       | 44.54 | 1.19    |
| E       | 52.27 | 1.32    |         |       |         |
| n ± SD  | 52.73±0.52 | 1.32±0.05 | n ± SD  | 33.86±7.17 (***) | 1.07±0.13 (**) |

Data are presented as mean with standard deviation. **denotes a statistically significant difference with p<0.01, and *** with p<0.001.

doi:10.1371/journal.pone.0064545.t001
unsaturated fatty acids; docosahexaenoic acid (DHA), palmitoleic acid and oleic acid (Fig. 1D).

Principal Component and Hierarchical Cluster Analysis
To study the statistically significant metabolic alterations in the fetal brain due to the induction of IUGR more in depth, both a principal component and hierarchical cluster analysis were performed based on the ion intensities of the 18 significant metabolites in the control and IUGR fetal brain tissue samples. The results of the PCA (Fig. 2) showed that the control (in blue) and IUGR (in red) fetal brain samples were clearly separated in two groups along the first three principal components of the score plot. The corresponding X-loading values (Table 3) revealed that the metabolites, aspargine, NAA, pyroglutamic acid (positive correlation) and palmitoleic acid (negative correlation) largely contributed to the cluster formation along the first principal component. The resulting heat map and dendrogram of the hierarchical cluster analysis (Fig. 3) also showed two main clusters that separated the control and IUGR fetal brain tissue samples. In addition both clusters were subdivided in smaller clusters, which largely reflected the different brain regions analyzed, creating groups of hemisphere, basal ganglia and brain stem tissue samples. Therefore the obtained results indicated that each brain region comprises a characteristic metabolite profile and that the induction of IUGR caused metabolic alterations in all brain regions. In general the PCA and hierarchical cluster analysis revealed the potential to distinguish between the normal and IUGR fetal brain based on the comprehensive measurement of its metabolic profile or status.

Correlations between Fetal Birth Weight and Metabolite Intensity Alterations
In the clinical setting, estimated fetal birth weight is used as a predictor for the severity of IUGR conditions. To investigate a potential relationship between fetal birth weight and metabolic alterations in the fetal brain of a rabbit IUGR model, the birth weight of the control and IUGR fetuses was correlated with the intensities of the 18 significantly altered metabolites. As expected, the results showed a negative relationship for the decreased metabolites and positive relationship for the metabolites that were

Figure 1. Metabolic differences between control and IUGR fetal brain tissue. Bar charts show the measured metabolite ion intensities of NAAG, NAA, pyroglutamic acid (A), ornithine, L-lysine, aspargine, histidine and 2-keto-isovalerate (B), succinate, panthothenate, malondialdehyde, 3-nitrotyrosine, purine and 3,4-Dihydroxybutyric acid (C), GMP, DHA, palmitoleic acid and oleic acid (D) in control (white bars) and IUGR (black bars) fetal brain tissue. All metabolite ion intensities were significantly different (p<0.05) based on a t-test followed by a Benjamini-Hochberg Multiple Testing Correction. Data are presented as mean, control (n = 5) and IUGR (n = 4) fetal brains with error bars representing standard deviation. doi:10.1371/journal.pone.0064545.g001
increased in the fetal IUGR brain. The highest correlation coefficients between birth weight and metabolite intensities were observed for the metabolites asparagine ($r^2 = 0.6723$, Fig. 4A), ornithine ($r^2 = 0.5422$), palmitoleic acid ($r^2 = 0.4938$), and N-acetylaspartylglutamate (NAAG) ($r^2 = 0.3712$) (Fig. 4D). The correlations also revealed that the brain tissue samples obtained from the IUGR fetus with the highest birth weight (fetus I; 44.45 g) included metabolite ion intensities more similar to the controls (Fig. 4A–D). This suggests that the observed alterations in metabolite ion intensities were dependent on the severity of the IUGR conditions, as reflected by fetal birth weight.

### Discussion

The present study applied a targeted metabolomics approach in a rabbit IUGR model to obtain improved insight into the effects of IUGR on the developing fetal brain and identify potential metabolite candidates to develop perinatal biomarkers for IUGR related abnormal neurodevelopment. Results showed that the induction of IUGR by 40–50% uteroplacental vessels ligation in the pregnant rabbit caused a significant decrease in the fetal birth weight and brain weight of the rabbit fetuses. These findings correspond with clinical observations in IUGR neonates, who besides a low birth weight were shown to have a decreased brain volume [27]. Therefore this study provides further supporting evidence that the rabbit IUGR model used is able to reproduce physiological features of the human IUGR condition and therefore could provide clinically relevant information regarding the effects of IUGR on fetal brain. Targeted metabolic profiling in the rabbit IUGR model showed that IUGR leads to statistically significant metabolic alterations in the fetal rabbit brain. The metabolic differences included ion intensity alterations in neurotransmitters/peptides, amino acids, fatty acids, energy metabolism intermediates and oxidative stress related metabolites. The identified alterations in brain metabolites could be useful to support the development of clinical biomarkers for the early perinatal diagnosis of IUGR related abnormal neurodevelopment and the discovery of potential therapeutic targets for fetal therapy.

Previous studies in animal model of the IUGR condition have shown that IUGR adversely affects brain development and organization [5–6]. The results obtained in this study showed a statistically significant decrease in the brain specific metabolites NAAG and NAA in the brain tissue of IUGR fetuses compared to control fetuses. NAAG and NAA are primarily present in neurons and oligodendrocytes and are well known markers for neuronal density and viability [20]. Moreover, NAA is synthesized in neuronal mitochondria and is therefore considered a marker for neuronal mitochondrial metabolism [29]. The observed decrease in NAAG and NAA metabolites therefore indicate that IUGR has a direct adverse effect on neurons and oligodendrocytes by perturbing neuronal viability, energy metabolism and the myelination process. These results are in agreement with previous brain histology studies in animal IUGR models, which demonstrated that IUGR adversely affected the myelination process [30] and caused the induction of neuronal cell death [6,31]. Moreover, a previous MRI study in the identical rabbit IUGR model observed a decrease in white matter myelination [26]. A potential adverse effect of IUGR on neuronal energy metabolism was supported by the identified decrease in the energy metabolism intermediates succinate and pantotheinic acid. Decreased succinate levels have been previously proposed as an indicative marker for disrupted neuronal energy metabolism in an Alzheimer’s disease mice model [32]. A study of brain metabolism in normal and IUGR fetuses using proton magnetic resonance spectroscopy also showed decreased NAA levels in the fetal IUGR brain [33]. Therefore the identified decrease in NAAG and NAA metabolites in the rabbit IUGR model further support previous findings that IUGR alters neuronal metabolism in the fetal brain.

Table 2. Metabolites with significantly different ion intensities in control and IUGR fetal brain tissue.

| Metabolite                               | P value | Mass   | Description                        |
|------------------------------------------|---------|--------|------------------------------------|
| Asparagine                               | 0.000242| 132.0534| Amino acid                         |
| Ornithine                                | 0.000275| 132.0894| Amino acid                         |
| Palmitoleic acid                         | 0.000372| 254.2249| Monounsaturated fatty acid         |
| 3-Nitrotyrosine                          | 0.000543| 226.0599| Marker of protein nitration        |
| N-Acetylaspartylglutamic acid (NAAG)     | 0.000632| 304.0914| Neurotransmitter                   |
| 2-keto-isovalerate                       | 0.001535| 116.0474| Leucine biosynthesis intermediate  |
| GMP                                      | 0.001535| 363.0578| Nucleotide                         |
| Histidine                                | 0.002027| 155.0695| Amino acid                         |
| Docosahexaenoic acid (DHA)               | 0.002243| 328.2408| Polysaturated fatty acid           |
| N-acetylaspartate                        | 0.002243| 175.0482| Neuropeptide                       |
| Purine                                   | 0.002375| 120.0426| Nitrogen containing heterocycle    |
| Oleic acid                               | 0.003172| 282.2564| Monounsaturated fatty acid         |
| L-Lysine                                 | 0.003892| 146.1056| Amino acid                         |
| Pyroglutamic acid                        | 0.003892| 129.0428| Precursor of glutamate             |
| Pantothenate                             | 0.003892| 219.1108| Precursor of coenzyme A            |
| Malondialdehyde                          | 0.004639| 72.02118| Lipid peroxidation marker          |
| Succinate                                | 0.005183| 118.0267| Citric acid cycle intermediate     |
| 3,4-Dihydroxybutyric acid                | 0.029617| 120.0425| Organic acid                       |

According to a t-test followed by a Benjamini-Hochberg Multiple Testing Correction.

doi:10.1371/journal.pone.0064545.t002

3-Nitrotyrosine 0.000543 72.02118 Lipid peroxidation marker
Pantothenate 0.003892 219.1108 Precursor of coenzyme A
Malondialdehyde 0.004639 72.02118 Lipid peroxidation marker
Succinate 0.005183 118.0267 Citric acid cycle intermediate
3,4-Dihydroxybutyric acid 0.029617 120.0425 Organic acid

PLOS ONE | www.plosone.org  May 2013 | Volume 8 | Issue 5 | e64545

Metabolic Alterations by IUGR in the Fetal Brain
Besides neurospecific metabolites, results showed a statistically significant decrease in the ion intensities of several amino acids in the fetal IUGR brain, including asparagine, histidine, ornithine, L-Lysine. Previous studies in animal models have already demonstrated that IUGR due to placental insufficiency causes a reduced placental transport of amino acids to the fetal blood circulation [33–35]. In addition, measurements of amino acids concentrations in maternal and fetal blood plasma of normal and IUGR pregnancies showed a significant reduction in amino acid levels in the blood plasma of IUGR fetuses [36]. The results obtained in this study suggest that IUGR can lead to reduced amino acid levels in the fetal brain of a rabbit model. Because amino acids are important for brain growth, metabolism and function, a potential reduction in the fetal brain could have a role in IUGR related abnormal neurodevelopment such as changes in brain volumes [27,37], connectivity patterns [9] and cognitive dysfunctions [11–12].

Metabolites found to be statistically significant increased in the IUGR fetal rabbit brain included the monounsaturated fatty acids palmitoleic acid, oleic acid and polyunsaturated fatty acid DHA. Both types of fatty acids are essential parts of brain cell membranes and myelin sheets and play a crucial role in neurodevelopment [38–40]. From animal and clinical studies it is known that fatty acids accumulate during pregnancy in the adipose tissue and brain of the developing fetus [41–42]. There have been few studies on brain fatty acid profiles in animal models of IUGR, one reported study in a rat IUGR model found no significant differences in fatty acid composition between the control and IUGR fetal brain [43]. In clinical studies however, it was shown that IUGR fetuses have higher levels of free fatty acids and triglycerides in blood plasma compared to normal fetuses, related to changes in lipid metabo-
Fetal brain lipid compositions in normal and IUGR pregnancies should clarify if the increased lipid levels detected in the rabbit model are clinically relevant.

Metabolic profiling also showed alterations in oxidative stress related metabolites including the lipid peroxidation marker malondialdehyde [45] and protein nitration marker 3-nitrotyrosine [46]. Although IUGR has been mostly shown to induce an oxidative stress response, both markers were found to be decreased in the fetal IUGR brain tissue. Since the redox status of a biological system changes rapidly, the levels of oxidative stress metabolites depend largely on the time point of measurement. It is likely that the release of hypoxic-ischemic conditions after delivery by cesarean section changed the dynamic oxidative stress related metabolism in the fetal brain. Therefore, it is difficult to interpret the measured alterations in the oxidative stress markers and draw any conclusions. Nevertheless the fact that both oxidative stress markers were among the significantly altered metabolites suggest that oxidative stress plays a role in the fetal brain under IUGR conditions. An improved study design allowing the in vivo measurement of oxidative markers in the fetal brain of the rabbit IUGR model would be required to obtain a detailed understanding of the oxidative stress response in the IUGR fetal brain.

Multivariate data analysis by PCA and hierarchical cluster analysis demonstrated that control and IUGR fetal brain tissue samples (from the identical pregnant rabbit) could be clearly distinguished based on their metabolite profiles. The PCA loadings indicated that the neuropeptide (NAA) amino acid (asparagine, ornithine) and fatty acid (palmitoleic acid) primarily contributed to the separation along the first principal component, which included most of the total variance in the dataset. These contributions make these metabolites interesting candidates for the development of clinical biomarkers using non-invasive clinical imaging techniques in the fetal brain. Even though the PCA results showed that IUGR had a global effect on the fetal rabbit brain by separating control and IUGR brain tissue samples from all studied brain regions, the metabolic differences were found to be predominant in the hemisphere brain regions. This suggests that the frontal brain regions are primarily susceptible for IUGR conditions, as was earlier suggested by clinical imaging [47] and behavioral studies [48].

**Table 3. The X-loading values for the first principal component of the PCA score plot.**

| Metabolite                  | PC1 (49.83%) value |
|-----------------------------|-------------------|
| Asparagine                  | 0.290             |
| NAA                         | 0.286             |
| Pyroglutamic acid           | 0.283             |
| Ornithine                   | 0.273             |
| 3-Nitrotyrosine             | 0.272             |
| NAAG                        | 0.271             |
| L-Lysine                    | 0.269             |
| Purine                      | 0.259             |
| Histidine                   | 0.258             |
| 3,4-Dihydroxybutyric acid   | 0.248             |
| 2-Keto-isovalerate          | 0.239             |
| Pantothenate                | 0.237             |
| Malondialdehyde             | 0.166             |
| Succinate                   | 0.162             |
| Oleic acid                  | −0.135            |
| GMP                         | −0.147            |
| Docosahexaenoic acid        | −0.155            |
| Palmitoleic acid            | −0.183            |

X-loading values show positive and negative correlations responsible for the cluster formation along the first principal component (PC1) in the PCA score plot.

doi:10.1371/journal.pone.0064545.t003
Strengths and Limitations

The main strength of this study includes the unique combination of a rabbit IUGR model and metabolomics approach. The rabbit IUGR model was previously shown to mimic the human IUGR condition. Furthermore, it enables a direct comparison of control and IUGR fetuses from the same mother. This study design reduces variability factors and avoids the requirements of large study groups of animals. Metabolomics can provide information on phenotypic outcomes of disease processes (IUGR conditions), which are highly relevant for biomarker candidate identifications. The sensitivity of the LC-QTOF-MS metabolomics technology allowed the detection of metabolite alterations related to subtle effects of IUGR conditions on the fetal brain. Limitations include the quantification of metabolites in brain tissue extracts instead of the tissue itself, therefore the measured metabolite levels might not correspond with in vivo concentrations. To overcome this limitation the in vivo metabolite levels should be determined by non-invasive techniques such as NMR or MRI spectroscopy. Nevertheless, these techniques do not have the sensitivity of the applied LC-QTOF-MS approach. As expected not all measured metabolites could be identified using the current up-to-date metabolite databases. Therefore, there could be additional metabolite candidates suitable for clinical biomarker development. The raw data of this study will be stored and as metabolite databases will expand there will be opportunities for additional metabolite identifications. Finally, this study was only able to provide a snapshot view of the dynamic metabolic processes in the fetal IUGR brain. To have a more comprehensive understanding of the progressive adverse effects of IUGR on the fetal brain, a larger scale time course metabolomics study would be required. Such a comprehensive analysis was beyond the scope of this initial study; however, the results here obtained encourage the performance of an extended metabolomic profiling study. Despite these limitations, the results of this study provide new mechanistic insights and demonstrate the potential to develop a prediction model for the effects of IUGR on the fetal brain based on tissue metabolic profiles.

From a clinical perspective, this study provides preliminary evidence supporting further research on the development of metabolic biomarkers associated with growth restriction and its neurodevelopmental correlates. Current challenges in fetal medicine include the correct classification of true growth restriction from physiologic smallness, particularly among fetuses with borderline estimated fetal weights. Such differentiation is critical to establish early-life intervention measures to correct for the impact of IUGR on neurodevelopment. Thus, it is imperative to develop classification algorithms. Likewise, biomarkers will be a critical need for the monitoring of the effectiveness of interventions in the correction of neurodevelopmental deviations. The design of such models will necessarily integrate clinical parameters, such as

Figure 4. Correlation graphs between fetal birth weight and metabolite ion intensities. The metabolites asparagine ($r^2 = 0.6723$) (A), ornithine ($r^2 = 0.5422$) (B), palmitoleic acid ($r^2 = 0.4938$) (C) and NAAG ($r^2 = 0.3712$) (D) showed the highest correlation coefficient. Brain tissue samples from IUGR fetus with the highest birth weight (I), showed metabolite intensities more similar to the controls. Each point represents a single fetal brain tissue sample.

doi:10.1371/journal.pone.0064545.g004
fetal birth weight and hemodynamic measures, together with more sophisticated blood or imaging biomarkers. Brain metabolic signatures could be determined by MRI spectroscopy and be useful markers as part of predictive scores to facilitate the perinatal diagnosis and monitoring of IUGR related abnormal neurodevelopment. Implementation of metabolomics technologies in clinical practice will require translational studies to demonstrate the feasibility of measuring metabolite candidates by means of non-invasive clinical imaging techniques in animal models and eventually patients.

In summary, this targeted metabolomics study demonstrates that IUGR leads to statistically significant metabolic alterations in the fetal rabbit brain, involving neuronal viability, energy metabolism, amino acid levels, fatty acid profiles and oxidative stress mechanisms. The identified metabolic alterations showed a dependence on the severity of IUGR conditions (reflected by birth weight) and allowed a clear discrimination between control and IUGR fetal brain tissue, which revealed the potential to develop biochemical biomarkers for the perinatal diagnosis of IUGR at its related abnormal neurodevelopment. Overall results identified asparagine, ornithine, NAAG, NAA and palmitoleic acid as the most promising metabolic candidates for further biomarker development studies based on non-invasive clinical imaging techniques.

Acknowledgments
We thank Dr. Magda Sanz for the critical reading of the manuscript.

Author Contributions
Conceived and designed the experiments: EVV EE MI EG. Performed the experiments: EVV EE MI AAP AGT HTH LZ. Analyzed the data: EVV HTH LZ. Wrote the paper: EVV HTH LZ TH EG.

References
1. Cruz-Lemini M, Crispì F, Van Mieghem T, Pedraza D, Cruz-Martinez R, et al. (2013) Risk of perinatal death in early-onset intrauterine growth restriction according to gestational age and cardiovascular Doppler indices: a multicenter study. Fetal Diagn Ther 32: 116–22.
2. Baschat AA (2004) Pathophysiology of fetal growth restriction: implications for diagnosis and surveillance. Obstet Gynecol Surv 59: 617–627.
3. Barker DJ (2005) fetal consequences of fetal growth restriction. Clin Obstet Gynecol 49: 270–283.
4. Crispì F, Bijjnens B, Figueras F, Bartrons J, Eixarch E, et al. (2010) Fetal growth restriction results in remodelled and less efficient hearts in children. Circulation 121: 2427–2436.
5. Rees S, Harding R, Walker D (2011) The biological basis of injury and neuroprotection in the fetal and neonatal brain. Int J Dev Neurosci 29: 551–563.
6. Rees S, Harding R, Walker D (2008) An adverse intrauterine environment: implications for injury and altered development of the brain. Int J Dev Neurosci 26: 3–11.
7. Esteban FJ, Padilla N, Sanz-Cortes M, de Miras JR, Bargallo N, et al. (2010) Fractal-dimension analysis detects cerebral changes in preterm infants with and without intratrophic growth restriction. Neuroimage 53: 1225–1232.
8. Padilla N, Falcon C, Sanz-Cortes M, Figueras F, Bargallo N, et al. (2011) Differential effects of intratrophic growth restriction on brain structure and development in preterm infants: a magnetic resonance imaging study. Brain Res 1302: 90–108.
9. Bataller D, Eixarch E, Figueras F, Munoz-Moreno E, Bargallo N, et al. (2012) Altered small-world topology of structural brain networks in infants with intratrophic growth restriction and its association with later neocortical development. Neuroimage 60: 1352–1366.
10. Dubois B, Beutch-Toka C, Cachia A, Lazarys F, et al. (2008) Primary cortical folding in the human newborn: an early marker of later functional development. Brain 131: 2028–2041.
11. Figueras F, Cruz-Martinez R, Sanz-Cortes M, Arranz A, Illa M, et al. (2011) Neurobehavioral outcomes in preterm, growth-restricted infants with and without prenatal advanced signs of brain-sparing. Ultrasound Obstet Gynecol 38: 258–294.
12. Bassan H, Stolar O, Geva R, Eshel R, Fattal-Valevski A, et al. (2011) Intrauterine growth-restricted neonates born at term or preterm: how different? Pediatr Neuro 44: 122–130.
13. Aarsmoe-Useng CS, Wiegela-Dupers N, van Golst J, Stolker J (2009) Meta-analysis of neurobehavioral outcomes in very preterm and/or very low birth weight children. Pediatrics 124: 717–729.
14. Thomsen E, Asad M, Ley D, Sjernsvik K, Munsal K (2011) Cognitive function after intratrophic growth restriction and very preterm birth. Pediatrics 127: e674–812.
15. Ah H, Duffy FH, McAnulty GB, Fischer CB, Kosta S, et al. (2011) Is the Newborn Individualized Developmental Care and Assessment Program (NIDCAP) effective for preterm infants with intrauterine growth restriction? J Perinatol 31: 130–136.
16. Ment LR, Hirtz D, Huppi PS (2009) Imaging biomarkers of outcome in the developing preterm brain. Lancet Neurol 8: 1042–1055.
17. Nicholson JK, Lindon JC, Holmes E (1999) ‘Metabonomics’: understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 29: 1181–1189.
18. Horgan RP, Clancy OH, Myers JE, Baker PN (2009) An overview of proteomic and metabolomic technologies and their application to pregnancy research. BJOG 116: 173–181.
19. Favretto D, Cosmi E, Ragazzi E, Vezzini S, Tucci M, et al. (2012) Cord blood metabolic profiling in intrauterine growth restriction. Anal Bioanal Chem 402: 1109–1121.
20. Dezi A, Atzori L, Noto A, Visser GH, Gazzolo D, et al. (2011) Metabolomics in newborns with intrauterine growth retardation (IUGR): urine reveals markers of metabolic syndrome. J Matern Fetal Neonatal Med 24 Suppl 2: 35–39.
21. Nissen PM, Nebel C, Obijobi N, Bertram HC (2011) Metabolomics reveals relationship between plasma inositols and birth weight: possible markers for fetal programming of type 2 diabetes. J Biomed Biotechnol.
22. Alexandre-Gousalbou MC, Courant F, Le Gall G, Moyon T, Darmann D, et al. (2011) Offspring metabolic response to maternal protein restriction in a rat model of intrauterine growth restriction (IUGR). J Proteome Res 10: 3292–3302.
23. Lin G, Liu C, Feng C, Fan Z, Dai Z, et al. (2012) Metabolomic analysis reveals differences in umbilical vein plasma metabolites between normal and growth-restricted fetal pigs during late gestation. J Nutr 142: 990–998.
24. Eixarch E, Figueras F, Hernandez-Aandrade E, Crispì F, Nadal A, et al. (2009) An experimental model of fetal growth restriction based on selective ligation of uteroplacental vessels in the pregnant rabbit. Fetal Diagn Ther 26: 203–211.
25. Drobyshovskiy A, Song SK, Gommerde G, Wyrwicz AM, Derrick M, et al. (2005) Developmental changes in diffusion anisotropy coincide with immature oligodendrocyte progression and maturation of compound action potential. J Neurosci 25: 3988–3997.
26. Eixarch E, Batalle D, Illa M, Munoz-Moreno E, Arbat-Plana A, et al. (2012) Neonatal neurobehavior and diffusion MRI changes in brain reorganization due to intrauterine growth restriction in a rabbit model. PLoS One 7: e13497.
27. Tola CB, Zimme S, Warfield SK, Freschi M, Sancho Rossoigna A, et al. (2004) Early alteration of structure and functional brain development in premature infants born with intrauterine growth restriction. Pediatr Res 56: 132–138.
28. Demougeot C, Marie C, Giroud M, Beley A (2004) N-acetylaspartate: a literature review of animal research on brain ischemia. J Neurochem 90: 776–783.
29. Benarroch EE (2008) N-acetylaspartate and N-acetylaspartylglutamate: neurobiology and clinical significance. Neurology 70: 1533–1537.
30. Tolcos M, Bateman E, O'Dowd R, Marwick R, Vrijen K, et al. (2011) Intrauterine growth restriction affects the maturation of myelin. Exp Neurol 232: 53–63.
31. Burke C, Sinclair K, Cogin G, Rose S, Pat B, et al. (2006) Intrauterine growth restriction due to uteroplacental vascular insufficiency leads to increased hypoxia-induced cerebral apoptosis in newborn piglets. Brain Res 1098: 19–25.
32. Forster DM, James MF, Williams SR (2012) Effects of Alzheimer’s disease transgenes on neurochemical expression in the mouse brain determined by 1H MRS in vitro. NMR Biomed 25: 52–58.
33. Storl L, Damodaram MS, Allop JM, McGuinness A, Patel A, et al. (2011) Brain metabolism in fetal intrauterine growth restriction: a proton magnetic resonance spectroscopy study. Am J Obstet Gynecol 205: 481–488.
34. Ross JC, Fenneveze PV, Wilkening RB, Battaglia FC, Meschia G (1996) Placental transport and fetal utilization of leucine in a model of fetal growth retardation. Am J Physiol 270: E491–503.
35. de Vrijer B, Regnault TR, Wilkening RB, Meschia G, Battaglia FC (2004) Placental uptake and transport of ACP, a neutral nonmetabolizable amino acid, in an ovine model of fetal growth restriction. Am J Physiol Endocrinol Metab 287: E1114–1124.
36. Castin I, Marcello AM, Corbetta C, Lanfranchi A, Bagnani AM, et al. (1992) Fetal amino acids in normal pregnancies and in pregnancies complicated by intrauterine growth retardation. Early Hum Dev 26: 183–186.
37. Lodygensky GA, Seghier ML, Warfield SK, Tolsa CB, Sizonenko S, et al. (2008) Intrauterine growth restriction affects the preterm infant’s hippocampus. Pediatr Res 63: 438–443.

38. Youdim KA, Martin A, Joseph JA (2000) Essential fatty acids and the brain: possible health implications. Int J Dev Neurosci 18: 383–399.

39. Georgieff MK, Innis SM (2005) Controversial nutrients that potentially affect preterm neurodevelopment: essential fatty acids and iron. Pediatr Res 57: 99R–103R.

40. Koletzko B, Lien E, Agostoni C, Bohles H, Campoy C, et al. (2008) The roles of long-chain polyunsaturated fatty acids in pregnancy, lactation and infancy: review of current knowledge and consensus recommendations. J Perinat Med 36: 5–14.

41. Green P, Glouzman S, Kamensky B, Yavin E (1999) Developmental changes in rat brain membrane lipids and fatty acids. The preferential prenatal accumulation of docosahexaenoic acid. J Lipid Res 40: 960–966.

42. Kuipers RS, Luxwolda MF, Offringa PJ, Martini IA, Boersma ER, et al. (2012) Gestational age dependent content, composition and intrapartum accretion rates of fatty acids in fetal white adipose tissue. Prostaglandins Leukot Essent Fatty Acids 86: 39–49.

43. Ikeno M, Okamura A, Hayakawa M, Kitamura Y, Suganuma H, et al. (2009) Fatty acid composition of the brain of intrauterine growth retardation rats and the effect of maternal docosahexaenoic acid enriched diet. Early Hum Dev 85: 733–735.

44. Akino G, Cozzi V, Radadli T, Ortega H, Herrera E, et al. (2008) Maternal and fetal fatty acid profile in normal and intrauterine growth restriction pregnancies with and without preeclampsia. Pediatr Res 64: 615–620.

45. Janero DR (1990) Malondialdehyde and thiobarbituric acid-reactivity, as diagnostic indices of lipid peroxidation and peroxidative tissue injury. Free Radic Biol Med 9: 515–540.

46. Darvish RS, Amirizade N, Arabii B (2007) Nitrotyrosine as an oxidative stress marker: evidence for involvement in neurologic outcome in human traumatic brain injury. J Trauma 63: 439–442.

47. Benavides-Serralde A, Hernandez-Andrade E, Fernandez-Delgado J, Plasencia W, Scheier M, et al. (2009) Three-dimensional sonographic calculation of the volume of intracranial structures in growth-restricted and appropriate-for-gestational age fetuses. Ultrasound Obstet Gynecol 33: 530–537.

48. Geva R, Eshel R, Leitner Y, Fatal-Valeski A, Harel S (2008) Verbal short-term memory span in children: long-term modality dependent effects of intrauterine growth restriction. J Child Psychol Psychiatry 49: 1321–133.